Stem definition | Drug id | CAS RN |
---|---|---|
5201 | 906673-24-3 |
None
None
Date | Agency | Company | Orphan |
---|---|---|---|
March 27, 2020 | EMA | Pfizer Europe MA EEIG | |
Dec. 14, 2016 | FDA | ANACOR PHARMS INC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Application site pain | 2118.81 | 71.76 | 330 | 2471 | 3468 | 50598855 |
Burning sensation | 702.67 | 71.76 | 204 | 2597 | 45242 | 50557081 |
Application site erythema | 258.49 | 71.76 | 58 | 2743 | 4480 | 50597843 |
Drug ineffective | 146.55 | 71.76 | 200 | 2601 | 819133 | 49783190 |
Application site pruritus | 134.59 | 71.76 | 33 | 2768 | 3726 | 50598597 |
Skin burning sensation | 127.06 | 71.76 | 39 | 2762 | 10146 | 50592177 |
Drug effective for unapproved indication | 127.05 | 71.76 | 28 | 2773 | 1981 | 50600342 |
Dermatitis atopic | 115.89 | 71.76 | 29 | 2772 | 3557 | 50598766 |
Application site swelling | 111.84 | 71.76 | 20 | 2781 | 478 | 50601845 |
Condition aggravated | 94.59 | 71.76 | 98 | 2703 | 296960 | 50305363 |
Eyelid irritation | 90.17 | 71.76 | 16 | 2785 | 365 | 50601958 |
Drug ineffective for unapproved indication | 88.51 | 71.76 | 36 | 2765 | 21245 | 50581078 |
Eczema | 86.26 | 71.76 | 36 | 2765 | 22666 | 50579657 |
Product use in unapproved indication | 76.63 | 71.76 | 58 | 2743 | 115761 | 50486562 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Application site pain | 1143.65 | 166.29 | 166 | 1014 | 1513 | 29571834 |
Burning sensation | 400.46 | 166.29 | 98 | 1082 | 15840 | 29557507 |
Application site erythema | 176.84 | 166.29 | 35 | 1145 | 2064 | 29571283 |
Drug ineffective | 166.52 | 166.29 | 126 | 1054 | 363044 | 29210303 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Application site pain | 2084.04 | 77.77 | 323 | 2687 | 3925 | 64491797 |
Burning sensation | 611.10 | 77.77 | 180 | 2830 | 49484 | 64446238 |
Application site erythema | 352.23 | 77.77 | 73 | 2937 | 4616 | 64491106 |
Drug ineffective | 309.47 | 77.77 | 275 | 2735 | 839972 | 63655750 |
Application site pruritus | 180.02 | 77.77 | 40 | 2970 | 3499 | 64492223 |
Condition aggravated | 145.00 | 77.77 | 127 | 2883 | 372299 | 64123423 |
Dermatitis atopic | 118.56 | 77.77 | 29 | 2981 | 3847 | 64491875 |
Drug ineffective for unapproved indication | 111.26 | 77.77 | 45 | 2965 | 31088 | 64464634 |
Skin burning sensation | 106.34 | 77.77 | 33 | 2977 | 10550 | 64485172 |
Application site swelling | 97.25 | 77.77 | 18 | 2992 | 624 | 64495098 |
Eczema | 96.11 | 77.77 | 40 | 2970 | 29680 | 64466042 |
Pruritus | 94.95 | 77.77 | 93 | 2917 | 312307 | 64183415 |
Off label use | 86.43 | 77.77 | 125 | 2885 | 632681 | 63863041 |
Erythema | 85.08 | 77.77 | 70 | 2940 | 187000 | 64308722 |
Application site irritation | 81.13 | 77.77 | 18 | 2992 | 1558 | 64494164 |
None
Source | Code | Description |
---|---|---|
ATC | D11AH06 | DERMATOLOGICALS OTHER DERMATOLOGICAL PREPARATIONS OTHER DERMATOLOGICAL PREPARATIONS Agents for dermatitis, excluding corticosteroids |
FDA MoA | N0000182960 | Phosphodiesterase 4 Inhibitors |
FDA EPC | N0000182961 | Phosphodiesterase 4 Inhibitor |
CHEBI has role | CHEBI:35475 | non-steroidal anti-inflammatory agent |
CHEBI has role | CHEBI:50748 | antipsoriatic drug |
CHEBI has role | CHEBI:68844 | phosphodiesterase IV inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Atopic dermatitis | indication | 24079001 | DOID:3310 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 7.8 | acidic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
2% | EUCRISA | ANACOR PHARMS INC | N207695 | Dec. 14, 2016 | RX | OINTMENT | TOPICAL | 8501712 | Feb. 16, 2027 | METHOD OF TREATING MILD TO MODERATE ATOPIC DERMATITIS. |
2% | EUCRISA | ANACOR PHARMS INC | N207695 | Dec. 14, 2016 | RX | OINTMENT | TOPICAL | 9682092 | Feb. 16, 2027 | METHOD OF TREATING MILD TO MODERATE ATOPIC DERMATITIS. |
2% | EUCRISA | ANACOR PHARMS INC | N207695 | Dec. 14, 2016 | RX | OINTMENT | TOPICAL | 8168614 | Jan. 20, 2030 | METHOD OF TREATING MILD TO MODERATE ATOPIC DERMATITIS. |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
2% | EUCRISA | ANACOR PHARMS INC | N207695 | Dec. 14, 2016 | RX | OINTMENT | TOPICAL | June 14, 2022 | PEDIATRIC EXCLUSIVITY |
2% | EUCRISA | ANACOR PHARMS INC | N207695 | Dec. 14, 2016 | RX | OINTMENT | TOPICAL | March 23, 2023 | NEW PATIENT POPULATION |
2% | EUCRISA | ANACOR PHARMS INC | N207695 | Dec. 14, 2016 | RX | OINTMENT | TOPICAL | Sept. 23, 2023 | PEDIATRIC EXCLUSIVITY |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Phosphodiesterase 4 | Enzyme | INHIBITOR | IC50 | 6.31 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A | Enzyme | IC50 | 5.21 | CHEMBL | |||||
High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A | Enzyme | IC50 | 6.14 | CHEMBL |
ID | Source |
---|---|
Q2R47HGR7P | UNII |
C4301781 | UMLSCUI |
CHEBI:134677 | CHEBI |
CHEMBL484785 | ChEMBL_ID |
44591583 | PUBCHEM_CID |
DB05219 | DRUGBANK_ID |
D10873 | KEGG_DRUG |
9151 | IUPHAR_LIGAND_ID |
1865953 | RXNORM |
248463 | MMSL |
32196 | MMSL |
724007009 | SNOMEDCT_US |
763593001 | SNOMEDCT_US |
4036360 | VANDF |
017053 | NDDF |
C543085 | MESH_SUPPLEMENTAL_RECORD_UI |
10024 | INN_ID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Staquis | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-2211 | OINTMENT | 20 mg | TOPICAL | EXPORT ONLY | 1 sections |
Eucrisa | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55724-211 | OINTMENT | 20 mg | TOPICAL | NDA | 27 sections |